Korro Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Korro Bio, Inc. on November 29, 2023, covering events occurring on November 27, 2023. The company is an emerging growth company incorporated in Delaware with its principal executive offices in Cambridge, MA. Its common stock trades on The Nasdaq Capital Market under the symbol KRRO.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Rachel Meyers, Ph.D., as a Class I director, effective November 27, 2023. Dr. Meyers was appointed by the Board of Directors upon the recommendation of the Nominating and Corporate Governance (NCG) Committee. Her term will last until the 2026 annual meeting of stockholders or until her successor is elected. Additionally, she was appointed as a member of the NCG Committee.
Compensation and Arrangements
Dr. Meyers will receive compensation as a non-employee director in accordance with the company's policy described in a prior Form 8-K filed on November 6, 2023. The company also entered into a standard indemnification agreement with Dr. Meyers, filed as Exhibit 10.7 to the November 6, 2023 filing, to indemnify her against certain expenses and amounts incurred in legal proceedings to the fullest extent permitted by law. The filing states there are no other arrangements or understandings regarding her selection and that she has no direct or indirect material interest in any transaction required to be disclosed under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the terms of the non-employee director compensation policy referenced in the November 6, 2023 Form 8-K (Exhibit 10.11).
- Review the standard indemnification agreement filed as Exhibit 10.7 to the November 6, 2023 Form 8-K.
- Confirm Dr. Meyers' professional background and qualifications as a Class I director.
- Check for any subsequent filings regarding the 2026 annual meeting of stockholders.